Olema Pharmaceuticals (OLMA) Total Debt (2025 - 2026)

Olema Pharmaceuticals (OLMA) posted quarterly Total Debt of $3.0 million for Q1 2026, little changed quarter-over-quarter from $3.0 million in Q4 2025.

Olema Pharmaceuticals (OLMA) Total Debt (2025 - 2026) Analysis & Trends

Olema Pharmaceuticals (OLMA) has reported Total Debt for 2 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Total Debt changed N/A year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
  • Total Debt steadied at $3.0 million in Q1 2026 per OLMA's latest filing, from $3.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $3.0 million in Q2 2025 and bottomed at $3.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.07 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.34 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 546.77 Mn
10 Olema Pharmaceuticals 930.10 Mn 930.10 Mn - 3.00 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 3.00 Mn
Mar 31, 2026 3.00 Mn
Dec 31, 2025 3.00 Mn
Sep 30, 2025 3.00 Mn
Jun 30, 2025 3.00 Mn